



(12) Translation of  
European patent specification

(11) NO/EP 2744332 B1

NORWAY

(19) NO  
(51) Int Cl.  
C07D 307/85 (2006.01)

**Norwegian Industrial Property Office**

---


- (21) Translation Published 2017.03.06
- (80) Date of The European Patent Office Publication of the Granted Patent 2016.10.26
- (86) European Application Nr. 12826498.3
- (86) European Filing Date 2012.08.10
- (87) The European Application's Publication Date 2014.06.25
- (30) Priority 2011.08.19, US, 201161525440 P  
2012.05.23, US, 201261650681 P
- (84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
- Designated Extension States: BA ME
- (73) Proprietor Glaxo Group Limited, 980 Great West Road Brentford, Middlesex TW8 9GS, GB-Storbritannia
- (72) Inventor CHONG, Pek Yoke, c/o GlaxoSmithKlineGlobal Patents DepartmentFive Moore Drive P. O. Box 13398, Research Triangle Park, North Carolina 27709, US-USA  
MILLER, John F., c/o GlaxoSmithKlineGlobal Patents DepartmentFive Moore DriveP. O. Box 13398, Research Triangle Park, North Carolina 27709, US-USA  
PEAT, Andrew James, c/o GlaxoSmithKlineGlobal Patents DepartmentFive Moore Drive P. O. Box 13398, Research Triangle Park, North Carolina 27709, US-USA  
SHOTWELL, John Brad, c/o GlaxoSmithKlineGlobal Patents DepartmentFive Moore Drive P. O. Box 13398, Research Triangle Park, NC 27709, US-USA
- (74) Agent or Attorney Bryn Aarflot AS, Postboks 449 Sentrum, 0104 OSLO, Norge
- 
- (54) Title **BENZOFURAN COMPOUNDS FOR THE TREATMENT OF HEPATITIS C VIRUS INFECTIONS**
- (56) References Cited: WO-A1-2009/101022  
WO-A2-01/02424  
US-A1- 2007 231 318

Enclosed is a translation of the patent claims in Norwegian. Please note that as per the Norwegian Patents Acts, section 66i the patent will receive protection in Norway only as far as there is agreement between the translation and the language of the application/patent granted at the EPO. In matters concerning the validity of the patent, language of the application/patent granted at the EPO will be used as the basis for the decision. The patent documents published by the EPO are available through Espacenet (<http://worldwide.espacenet.com>) or via the search engine on our website here: <https://search.patentstyret.no/>

## Patentkrav


1. Forbindelse som er metyl 5-(N-(5-cyklopropyl-2-(4-fluorfenyl)-3-(metylkarbamoyl)benzofuran-6-yl)metylsulfonamido)-2-nitrobenzoat, som har

5 strukturen




2. Forbindelse som er metyl 2-amino-5-(N-(5-cyklopropyl-2-(4-fluorfenyl)-3-(metylkarbamoyl)benzofuran-6-yl)metylsulfonamido)benzoat, som har strukturen

10




3. Forbindelse som er metyl 2-amino-3-klor-5-(N-(5-cyklopropyl-2-(4-fluorfenyl)-3-(metylkarbamoyl)benzofuran-6-yl)metylsulfonamido)benzoat, som har strukturen

15



4. Forbindelse som er metyl 2-brom-3-klor-5-(N-(5-cyklopropyl-2-(4-fluorfenyl)-3-(metylkarbamoyl)benzofuran-6-yl)metylsulfonamido)benzoat, som har strukturen

20



5. Forbindelse som er 6-(N-(4-brom-3-klor-5-((metoksymetoksy)metyl)fenyl)metylsulfonamido)-5-cyklopropyl-2-(4-fluorfenyl)-N-metylbenzofuran-3-karboksamid, som har strukturen

